Nontypeable *Haemophilus influenzae* newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct

Elaine M. Mokrzan, Christian P. Ahearn, John R. Buzzo, Laura A. Novotny, Yan Zhang, Steven D. Goodman, Lauren O. Bakaletz

*Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA*

**ABSTRACT**

Biofilms contribute significantly to the chronicity and recurrence of bacterial diseases due to the fact that biofilm-resident bacteria are highly recalcitrant to killing by host immune effectors and antibiotics. Thus, antibody-mediated release of bacteria from biofilm residence into the surrounding milieu supports a powerful strategy to resolve otherwise difficult-to-treat biofilm-associated diseases. In our prior work, we revealed that antibodies directed against two unique determinants of nontypeable *Haemophilus influenzae* (NTHI) [e.g. the Type IV pilus (T4P) or a bacterial DNABII DNA-binding protein, a species-independent target that provides structural integrity to bacterial biofilms] release biofilm-resident bacteria via discrete mechanisms. Herein, we now show that the phenotype of the resultant newly released (or NRel) NTHI is dependent upon the specific antibody directed against two unique determinants of nontypeable *Haemophilus influenzae* (NTHI) [e.g. the Type IV pilus (T4P) or a bacterial DNABII DNA-binding protein, a species-independent target that provides structural integrity to bacterial biofilms] release biofilm-resident bacteria via discrete mechanisms. Herein, we now show that the phenotype of the resultant newly released (or NRel) NTHI is dependent upon the specific mechanism of release. We used flow cytometry, proteomic profiling, and targeted transcriptomics to demonstrate that the two NRel populations were significantly different not only from planktonically grown NTHI, but importantly, from each other despite genetic identity. Moreover, each NRel population had a distinct, significantly increased susceptibility to killing by either a sulfonamide or β-lactam antibiotic compared to planktonic NTHI, an observation consistent with their individual proteomes and further supported by relative differences in targeted gene expression. The distinct phenotypes of NTHI released from biofilms by antibodies directed against specific epitopes of T4P or DNABII binding proteins provide new opportunities to develop new targeted therapeutic strategies for biofilm eradication and disease resolution.

**Introduction**

The Centers for Disease Control and Prevention and the National Institutes of Health estimate that biofilms contribute to the pathogenesis of ~80% of all bacterial infections [1]. Biofilm-associated diseases such as otitis media (OM), cystic fibrosis, chronic obstructive pulmonary disease, chronic rhinosinusitis, chronic wound infections, periodontitis, cystitis and infections of medical implants and indwelling catheters, among many others, are typically chronic and/or recurrent due to the presence of bacteria within biofilms that are highly resistant to killing by host immune effectors and antibiotics [2,3]. Our laboratory has primarily focused on diseases of the upper and lower respiratory tracts caused by nontypeable *Haemophilus influenzae* (NTHI) wherein a biofilm contributes significantly to each disease course [4–6]. An example of one such disease wherein NTHI is the predominant pathogen is OM [7–11], the most common bacterial disease in children [12,13]. The role of biofilms in OM pathogenesis, chronicity and recurrence is widely accepted. Nonetheless, like most NTHI-induced diseases, OM is still commonly...
treated with broad-spectrum oral antibiotics, which do not reach sufficient levels in the middle ear (or other sites) to eradicate biofilms or even the planktonically growing bacteria within this anatomical niche [14]. Although their use is sometimes indicated or necessary, broad-spectrum antibiotics can also cause collateral damage in the form of skin rashes, diarrhea and life-long disruption of the gut microbiome, with accompanied immunological and/or developmental consequences [15–17]. Moreover, the all too common indiscriminate and often ineffective use of antibiotics contributes greatly to the globally burgeoning problem of development of multiple antibiotic-resistant bacteria [18–20].

Delivery of vaccines is the most cost-effective way to manage infectious diseases as these target prevention [21], and as such, vaccine development remains a viable and truly ideal goal. However, for those children and adults with existing biofilm-associated chronic or recurrent infections, an effective therapeutic approach is greatly needed. In our long-standing efforts to develop a vaccine for diseases of the respiratory tract caused by NTHI, we focused on two unique, biofilm-associated determinants. Our first target is the NTHI T4P, a critical adhesin with multiple roles in adherence, colonization, biofilm formation, twitching motility and competence [22–28]. Antibodies against the majority subunit of NTHI T4P (PilA), specifically a recombinant and soluble form of PilA (rsPilA), induce dispersal of pre-existing NTHI as well as polymicrobial biofilms in vitro, and also those present within the middle ear in a chinchilla model of NTHI-induced OM wherein biofilm dispersal leads to rapid disease resolution [29–34]. The mechanism for this outcome requires expression of both T4P and LuxS, the latter mediates quorum sensing in NTHI [35–37]. Armbruster et al. showed that LuxS-induced production of the quorum-sensing molecule autoinducer 2 (AI-2) leads to increased biofilm formation in vitro and persistence in vivo in a chinchilla model of OM [35], and further revealed that NTHI takes up AI-2 from its environment via RhsB [38]. The role of LuxS-mediated AI-2 signaling in biofilm maturation and prevention of biofilm dispersal was further demonstrated by Pang et al., who used an NTHI construct wherein LuxS expression was inducible [39].

Our studies revealed an additional role for LuxS quorum signaling specifically during biofilm dispersal induced by anti-rsPilA antibodies, which requires both NTHI T4P expression and LuxS-induced production of AI-2 [33]. NTHI are released in a “top down” process, with maximal dispersal into the supernatant within 6 h of incubation [29,33]. Armbruster et al. also showed that Moraxella catarrhalis, which does not express AI-2, nonetheless “eavesdrops” on the AI-2 signal produced by NTHI within a polymicrobial biofilm formed by these two species, which leads to increased M. catarrhalis biofilm formation [40]. Intriguingly, when we incubated a pre-formed dual-species NTHI plus M. catarrhalis biofilm with antibody directed against rsPilA (to target an antigen expressed exclusively by NTHI), both NTHI and M. catarrhalis were dispersed from the biofilm [29]. The mechanism for M. catarrhalis dispersal revealed another example wherein M. catarrhalis had eves-dropped on the AI-2 produced by NTHI in response to exposure to anti-rsPilA [29].

Our second target, Integration Host Factor (IHF), is a critical structural element of the bacterial biofilm matrix. IHF and HU (a histone-like protein) comprise the ubiquitous two-membered DNABII family of bacterial DNA-binding proteins. Genes that encode IHF and/or HU are present in the genome of every member of Eubacteria [41]. Hence, this target is not unique to NTHI but is instead species-independent due to its presence in all tested pathogen-formed biofilms to date, including each of the high-grade intravenous infection pathogens Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. [42–44]. Extracellular DNA (eDNA) and associated DNABII proteins are essential to the underlying architecture and structural integrity of these biofilms [3,45–47]. Within the biofilm matrix, crossed strands of eDNA are stabilized by IHF and HU [45]. The result is a lattice-like eDNA scaffold that supports and maintains the biofilm architecture. Exposure of bacterial biofilms to antibiotics leads to antibiotic DNA-binding protein destabilizes the eDNA matrix and causes collapse of the biofilm structure [45]. The mechanism for this outcome is induction of an equilibrium shift wherein DNABII molecules in the milieu that surrounds the biofilm are sequestered due to formation of an antibody complex, thus DNABII proteins within the eDNA matrix are released [32,48].

The result is a sudden, complete collapse of the eDNA scaffold and release of the biofilm-resident bacteria that begins within 3 min of exposure to anti-DNABII antibodies in vitro [48,49]. Vaccination-induced antibodies against DNABII proteins disrupt pre-existing biofilms in a chinchilla model of NTHI-induced OM which permits clearance by host immune effectors [32,45,49]. Moreover, therapeutic treatment with anti-DNABII antibodies resolves osteolytic peri-implantitis in a rat model of pre-existing Aggregatibacter actinomycetemcomitans biofilms [50], and also eradicates aggregate biofilms of P. aeruginosa from the murine lung [32].

Despite the fact that the mechanisms and kinetics of the two targeted antigens used here are very different, the outcome of exposure of NTHI biofilms to anti-rsPilA antibodies or anti-DNABII antibodies is release of NTHI from biofilm residence into the surrounding milieu. Pioneering work from several laboratories reveals that bacteria released from a biofilm demonstrate a distinct phenotype from their biofilm-resident or planktonic counterparts [51–53]. Of note, a common characteristic of these released bacteria is sensitivity to antibiotic killing greater than that shown by even planktonically grown bacteria [29,48,54,55]. Intriguingly, whereas P. aeruginosa released from a biofilm by exposure to either glutamate or nitric oxide showed variable sensitivity to tobramycin and/or colistin compared to each other, both populations were more sensitive to antibiotic killing than their planktonic counterparts [54,56]. We showed that NTHI and M. catarrhalis released from a dual species biofilm by anti-rsPilA antibodies are significantly more sensitive to killing by either trimethoprim plus sulfamethoxazole or clarithromycin, respectively, than their agar-grown counterparts [29]. Moreover, NTHI biofilms exposed to anti-DNABII antibodies in combination with antibiotics significantly augments killing of the newly released NTHI by all three first-line antibiotics used to treat OM (e.g. ampicillin, amoxicillin-clavulanate, cefdinir) in vitro [48]. Further, our in vivo studies demonstrate that treatment with anti-DNABII antibodies in combination with the aminoglycoside antibiotic tobramycin confers an added benefit to the eradication of P. aeruginosa from the murine lung compared to treatment with antibodies or antibiotic alone [32].

Herein we used NTHI as a model organism to further characterize the phenotype of newly released bacteria, hereafter referred to as ‘NRel’. Given the unique ways in which NTHI are released from biofilms by anti-rsPilA compared to anti-DNABII antibodies, we used comparative analysis of abundances of all expressed proteins (as determined by quantitative mass spectrometry), targeted transcriptomics, flow cytometry and susceptibility to killing by a sulfonamide or β-lactam antibiotic to investigate whether anti-rsPilA induced NRel NTHI [33] were phenotypically different than anti-DNABII induced NRel NTHI [48], despite the genetic identity of these two populations.

Material and methods

Collection and quantitation of NRel NTHI

Nontypeable Haemophilus influenzae strain 86-028NP is a clinical isolate recovered from the nasopharynx of a child undergoing tympanostomy tube insertion due to chronic OM [57,58] and has been maintained frozen at a low passage number. NTHI biofilms were established in brain heart infusion broth supplemented (bBHI) with 2 μg each of β-nicotinamide adenine dinucleotide (β-NAD) and heme per ml for 16 h in 8-well chambered coverglass slides as described [59]. After 16 h, biofilms were washed with 200 μl of equilibrated (37 °C) Dulbecco’s phosphate buffered saline without calcium or magnesium (DPBS). To collect and enumerate NRel, 16 h NTHI biofilms were gently washed, then incubated with 11 μg rabbit polyclonal IgG derived from anti-rsPilA antiserum (generated against rsPilA expressed by NTHI strain
86-028NP) [30] for 6 h (‘anti-rsPilA NRel’) or 5.0 μg rabbit polyclonal IgG derived from anti-native IHF antiserum (generated against native IHF expressed by NTHI strain 86-028NP) [30] for 15 min (‘anti-IHF NRel’), antibodies were diluted in pre-warmed equilibrated (37 °C, 5% CO2) sBHI. These amounts of IgG match the IgG concentration present within a frozen and stored at reduce with 10 mM dithiothreitol at 60 °C. Post incubation times used coincide with the sBHI. These amounts of IgG match the IgG concentration present within a frozen and stored at

Sample preparation for LC-MS/MS

Anti-rsPilA NRel and anti-IHF NTHI were collected as described above. Planktonic NTHI were incubated statically in sBHI until mid-log phase of growth. Samples were centrifuged for 4 min at 13,200 × g, resuspended in 1 ml DPBS and centrifuged again. Pellets were flash frozen and stored at -80 °C. All further processing was done by MS Bioworks, LLC (Ann Arbor, MI) as described next.

Cell pellets were suspended in buffer (2% sodium dodecyl sulfate, 150 mM NaCl, 50 mM Tris pH 8), lysed with a sonic probe (Q Sonica, Newtown, CT) and heated at 100 °C for 10 min. Protein concentration of the extract was determined by Qubit fluorometry, and 10 μg of each sample was processed by SDS-PAGE using a 10% Bis Tris NuPage mini-gel (Invitrogen) in the MES buffer system. The migration windows (1 cm gel lane) were excised and digested in-gel with trypsin using a Pro-Geist robot (DigiLab, Hopkinton, MA) with the following protocol: 1) wash with 25 mM ammonium bicarbonate followed by acetonitrile; 2) reduce with 10 mM dithiothreitol at 60 °C followed by alkylation with 50 mM iodoacetamide at room temperature; 3) digest with trypsin (Promega, Madison, WI) at 37 °C for 4 h; 4) quench with formic acid. Supernatants were analyzed directly without further processing.

Mass spectrometry

Half of each pooled fraction was analyzed by nano LC-MS/MS with a Waters M-Class HPLC system interfaced to a ThermoFisher Fusion Lumos mass spectrometer. Peptides were loaded on a trapping column and eluted over a 75 μm analytical column at 350 nL/min; both columns were packed with Luna C18 resin (Phenomenex, Torrance, CA). The mass spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the Orbitrap at 60,000 FWHM (full width at half maximum) resolution and 15,000 FWHM resolution, respectively. The instrument was run with a 3 s cycle for MS and MS/MS. Two hours of instrument time was employed for the analysis of each sample.

Mass spectrometry data processing

Data were searched using a local copy of Mascot (Matrix Science) with the following parameters: enzyme, trypsin/P; database, https://www.ncbi.nlm.nih.gov/nuccore/CP000057.2 (concatenated forward and reverse plus common contaminants); fixed modifications, carboxymethyl (C), variable modifications: acetyl (N-term), deamidation (N, Q), oxidation (M), pyro-glu (N-term Q); mass values, monoisotopic; peptide mass tolerance, 10 ppm; fragment mass tolerance, 0.02 Da; maximum missed cleavages, 2. Mascot DAT files were parsed into Scaffold (Proteome Software) for validation, filtering and to create a non-redundant list per sample. Data were filtered using a 1% protein and peptide false discovery rate (FDR), requiring at least two unique peptides per protein. We used the normalized spectral counts for downstream analysis. To evaluate the variation and reproducibility in the replicates, we generated the PCA plot with 95% confidence ellipses surrounding each population (using the FactoMineR and ggplot2 packages in R), with the normalized spectral counts for each protein identified by mass spectrometry in the three samples of planktonic, anti-rsPilA NRel, and anti-IHF NRel groups [60,61].

Differential expression analysis

Normalized spectral counts from three biological replicates of the three sample groups (planktonic, anti-rsPilA NRel and anti-IHF NRel), were used for pairwise comparisons to determine the differential expression of each protein using a two-tailed t-test. The P-values, Benjamini-Hochberg adjusted P-values, and fold changes are provided (Supplementary data set 1). Proteins with >1.5-fold increase or decrease and with an associated P < 0.05 were considered to be significantly different in expression. NTHI strain 86-028NP proteins were annotated by Clusters of Orthologous Groups of proteins [62,63].

Antibiotic sensitivity of biofilm-resident, planktonic or NRel NTHI

As we had hypothesized that NRel would be more sensitive than planktonic NTHI to certain antibiotics, we set the baseline for planktonic killing to 25% so that we would be able to demonstrate a dynamic range in NRel killing by a given antibiotic. To avoid excessive manipulation or dilution of NRel NTHI, and to permit direct comparison of equal numbers of planktonic and NRel, we adjusted the planktonic cell density to the same CFU per ml as the NRel population in each experiment as follows: NTHI were incubated statically to mid log phase growth then diluted to either 3 × 10⁸ CFU/ml for comparison with anti-rsPilA NRel collected at 6 h, or to 2 × 10⁷ CFU/ml for comparison with anti-IHF NRel collected at 15 min (see Fig. 1). We then determined the concentrations of amoxicillin (Sigma-Aldrich, St. Louis, MO) and clavulanate (U.S. Pharmacopeia, Rockville, MD), or of trimethoprim (Sigma-Aldrich) and sulfamethoxazole (Santa Cruz Biotech, Dallas, TX) that killed approximately 25% of planktonic NTHI at each density. The same antibiotic concentrations were used for the anti-IHF or anti-rsPilA NRel, the density-matched (same CFU/ml) planktonic NTHI, and the adherent biofilm for each relevant experiment. Likewise, for anti-IHF or anti-rsPilA NRel collected at 2 h, we first quantitated NRel, and found ∼2.0 × 10⁸ or 4.0 × 10⁹ CFU/ml released by exposure of biofilms to anti-rsPilA or anti-IHF IgG, respectively. We then assessed killing of anti-IHF or anti-rsPilA NRel by concentrations of amoxicillin plus clavulanic acid (“augmentin”, AMC) or trimethoprim plus sulfamethoxazole (TMP-SMX) that killed 25% of the planktonic NTHI at the same density.

Anti-rsPilA or anti-IHF NRel were collected and sonicated as described above. After sonication for 2 min in a water bath sonicator to break up any NTHI aggregates, NRel or planktonic NTHI were incubated with the indicated antibiotics at 37 °C for 2 h, then serially diluted and plated on chocolate agar to quantify viable NTHI. To assay biofilm-resident NTHI, biofilms were established for 16 h at 37 °C as described above, washed twice with DPBS and incubated in sBHI supplemented with the indicated antibiotics at 37 °C. After 2 h, biofilm-resident NTHI were collected by forceful pipetting, sonicated for 2 min and enumerated as described above. All experiments were performed at least three times on separate days with two or three technical replicates for each treatment and control group.

Flow cytometry

As described above, NTHI biofilms were established in 8-well chambered coverglass slides. After 16 h, medium was aspirated from each well.
and biofilms incubated with 5 μg IgG from rabbit polyclonal IHF for 15 min or 11 μg IgG from polyclonal rabbit anti-rsPilA for 6 h at 37 °C, 5% CO₂. At each respective timepoint, 190 μl of supernatant above each biofilm was collected, transferred into 1 μM FM1-43FX (Invitrogen, Carlsbad, CA) in Hank’s Balanced Salt Solution and incubated static for 15 min at room temperature. NTHI scraped from a chocolate agar plate into buffer served as a ‘clumped’ bacterial control. NTHI suspended in buffer by gentle pipetting followed by sonication for 5 min served as a ‘non-clumped’ bacterial control. Forward scatter and side scatter profiles of fluoro-rescently stained NTHI were examined with a BD LSR II flow cytometer and FlowJo software. 10,000 events were collected for each sample.

RNA isolation and qRT-PCR assay

For RNA isolation, we seeded 6 ml of NTHI at 2 × 10⁶ CFU/ml into a T-25 tissue culture flask. After 16 h incubation at 37 °C, 5% CO₂, the flask was gently inverted, and the medium poured off. With the flask upside down, 6 ml prewarmed DPBS was added then the flask was slowly inverted to gently wash the biofilm. To remove the DPBS wash, the flask was inverted again and DPBS poured off. Antibody diluted in sBHI was added with the flask still upside down, to deliver the same concentration of antibody/cm² as used in chamberslide assays [this translated to ~52 μg anti-IHF IgG per ml or ~113 μg anti-rsPilA IgG per ml]. The flask was returned to the incubator, inverted gently so that the medium again covered the biofilm. After 3 min for anti-IHF, or 3 h for anti-rsPilA, the flask was inverted and the NRel NTHI collected by pouring into a 15 ml conical tube. NRel were centrifuged for 1 min at 16,000 × g, the supernatant aspirated, and 1 ml TRIzol™ Reagent (ThermoFisher, Waltham, MA) was immediately added to the bacterial pellet. Samples were stored at −80 °C.

RNA was purified with a Qiagen RNeasy kit (Qiagen, Germantown, MD). Residual DNA was removed by treatment with DNase I (NEB, Ipswich, MA), per manufacturer’s instructions for 45 min at 37 °C in the presence of 20 U SUPERase In RNase inhibitor (Ambion, Austin, TX). Relative gene expression was assessed by quantitative reverse transcription-PCR (qRT-PCR) with a Superscript III Platinum SYBR Green One-Step qRT-PCR kit (ThermoFisher) per manufacturer. Gene expression was normalized to 16S, and relative expression was calculated by the comparative (ΔΔC_t) method, with fold change in gene expression expressed as 2ΔΔC_t. Results represent the mean of 3 biological samples, each assayed in triplicate. A 2-fold change in gene expression was considered biologically significant. Primers used are listed in Table 1.

Statistical analyses

Data are expressed as mean ± SEM of at least three biological replicates performed on separate days with two or three technical replicates per sample. Statistical analyses were performed with GraphPad (Prism) software version 8.2. Multiple comparisons were made by one-way analysis of variance with the Holm-Sidak correction. All other comparisons were made with student’s t-test. Comparisons of fold changes in normalized spectral counts of proteins identified by mass spectrometry and generation principal component analysis were performed in R (Bioconductor). Flow cytometry data were analyzed by the Kolmogorov-Smirnov test to compare the cumulative distribution of anti-rsPilA NRel versus anti-IHF NRel for forward scatter and side scatter profiles.

Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information files (Suppl. Table 1 & Suppl. Dataset 1).

Results

Incubation of NTHI biofilms with anti-rsPilA or anti-IHF antibodies released NTHI from biofilm residence

Anti-rsPilA antibodies specifically target PilA, the majority subunit of NTHI T4P [33], to induce a more gradual, top-down release of NTHI from the biofilm which we refer to as ‘dispersal’ as this is a programmed process that requires active NTHI participation by expression of both T4P and AI-2-dependent signaling [33]. In contrast, anti-IHF antibodies

| Table 1 |
|---|
| Primers used in this study. |
| Primer | Sequence |
| achr-forward | CGCGGATAAAATTTACCTCGTGA |
| achr-reverse | TGAACTGACCCGGAAGAG |
| artM-forward | GTCTATATGCTAGGTTTCT |
| artM-reverse | GGATGCTATGCGCGTCCCTTA |
| deaD-forward | TGTGGTAATCTACGACATCC |
| deaD-reverse | GATCTGGATCTTGAGAATAA |
| emmA-forward | CGCAAGGATTACGACATGAC |
| emmA-reverse | ATTCAGAGGGCCAGCATAG |
| emmβ-forward | CGTTAACCTTTGAGCACTCA |
| emmβ-reverse | GCGCAGACGTTATGATTAG |
| fis-forward | TATACCGGCGATGCTCTAC |
| fis-reverse | CCCGGTTGGATTACCGAGATAT |
| folA-forward | TGGTGGTGGACCTACCATGTAAC |
| folA-reverse | GACGCCATTTCACAGTAATC |
| folB-forward | TGGTGGATCTTGACATATT |
| folB-reverse | TGGTGGATCTTGAGAATAA |
| 16S-forward | AAGAGAGACTCGCGAGATATA |
| 16S-reverse | CCCCCTCTATAGCGAGCTTTAG |

Fig. 1. Quantitation of NTHI released from biofilm residence by either anti-rsPilA or anti-IHF. NTHI biofilms established for 16 h were incubated for an additional (a) 6 h with rabbit anti-rsPilA IgG or (b) 15 min with rabbit anti-IHF IgG or with each of three negative controls (sBHI, IgG isolated from naive serum or IgG isolated from anti-OMP PS serum) followed by quantitation of NTHI recovered from supernatants above the biofilms. Anti-rsPilA and anti-IHF induced significant release of NTHI from biofilm residence into the NRel state. Individual data points are shown, bars represent mean ± SEM, ***, P < 0.0001, One-way analysis of variance with the Holm-Sidak correction.
induce a rapid, non-programmed, species-independent, biofilm matrix collapse with immediate release of bacteria en masse, we refer to as ‘disruption’ [45,48]. This latter outcome does not require bacterial action Table 2 [32,43-45]. To now expand further on this understanding, we first quantified the number of NTHI released from biofilm residence after incubation with rabbit polyclonal IgG isolated from either anti-rsPilA or anti-IHF serum. Sterile culture medium or an equivalent concentration of polyclonal IgG recovered from either naïve serum or from antiserum against the NTHI adhesin outer membrane protein P5 (OMP P5), none of which disperse established NTHI biofilms [29,33], served as negative controls. Our prior work reveals that NTHI biofilms established for 16 h and incubated with anti-rsPilA are maximally dispersed after 6 h [29,33], whereas complete collapse of a similarly aged biofilm is achieved after 15 min with anti-IHF [49]. Thus, for this assay, NRel induced by anti-rsPilA or anti-IHF were collected for enumeration at either 6 h or 15 min, respectively [29,33,49].

The concentration of NTHI recovered from supernatants above biofilms that had been incubated with polyclonal IgG from either naïve or anti-OMP P5 serum was similar to that when incubated with sterile sBHI [Fig. 1a and b]. This was anticipated as none of these three treatments were expected to significantly alter the normal equilibrium wherein bacteria go on/come off a biofilm as a natural part of biofilm growth and remodeling within the 6 h or 15 min incubation periods. Conversely, incubation with anti-rsPilA IgG for 6 h induced a significant >2-fold increase in the concentration of released NTHI (Fig. 1a, P < 0.0001). Similarly, incubation with anti-IHF IgG for 15 min resulted in a significant >3-fold increase in concentration of released NTHI (P < 0.0001) [Fig. 1b]. The lower concentration of the 3 control populations, compared to those similarly depicted in Fig. 1a, reflects the shorter 15 min incubation period. We refer to the concentration of these NTHI newly released from biofilm-residence as ‘anti-rsPilA NRel’ or ‘anti-IHF NRel’ to reflect their generation due to the action of two unique and specifically-targeted antibodies wherein the mechanisms and kinetics of release of biofilm resident NTHI are different [Table 2].

FACS analysis of anti-rsPilA and anti-IHF NRel populations

As hypothesized and based on gross observations of the NRel populations as they were recovered, the scatter profiles for anti-rsPilA NRel and anti-IHF NRel are also distinct. We performed flow cytometry and examined the forward scatter and side scatter profiles for each NRel population to reveal potential differences in size and complexity. The scatter profile for a suspension of NTHI that was briefly sonicated prior to assessment revealed a population of cells of similar size (i.e. single cells), whereas a larger and more complex population (i.e. aggregates) was additionally observed in the sample with bacterial aggregates, indicative of bacterial aggregates and/or biofilm remnants [Fig. S1, panel e]. Moreover, the anti-IHF NRel population was 10% larger in size [Fig. S1, panel d] and 47% more complex [Fig. S1, panel e] compared to the anti-rsPilA NRel, further evidence of distinct character of each population. Moreover, these data fit well with the described differences for how each antiserum mediates release of NTHI from biofilm residence (Table 2) as the programmed release mediated via disruption would indeed favor release as individual cells, whereas the rapid physical collapse of the biofilm to release NTHI via disruption would favor release as aggregates.

Proteomic expression profiles of anti-rsPilA and anti-IHF NRel were distinct from both their planktonically grown counterparts and importantly, from each other.

Given our ultimate interest in the relative sensitivity of NRel NTHI to killing by antibiotics, next we questioned how the anti-rsPilA and anti-IHF NRel populations compared phenotypically to not only planktonically grown NTHI (the population used clinically to determine antibiotic sensitivities, or MIC values), but also to each other. To begin to address this central question, we examined the proteomic expression profiles of anti-rsPilA NRel, anti-IHF NRel and planktonic NTHI (grown statically in broth to mid-log phase) by mass spectrometric analysis. The total proteomic expression profiles for anti-rsPilA and anti-IHF NRel were different from planktonic NTHI, as shown by the discrete locations of each population on the principal component analysis (PCA) plot [Fig. 2a]. Moreover, although we had anticipated that NRel population proteomic profiles would be different from planktonic cells [29,48], the two NRel populations were also very different from each other, as highlighted by the 95% confidence ellipses, despite genetic identity.

Due to the overall global changes in protein expression between the anti-rsPilA or anti-IHF NRel and planktonically grown NTHI, we next examined proteins with differences in abundance between the two NRel populations, after each was first compared to planktonic NTHI. There was a total of 63 and 103 differentially expressed proteins (DEPs) with a significant >1.5-fold increase or decrease in abundance compared to planktonic NTHI (P < 0.05) in anti-rsPilA NRel and anti-IHF NRel populations, respectively [Fig. 2b & Suppl. Table 1]. Moreover, anti-rsPilA NRel expressed 40 proteins and anti-IHF NRel expressed 80 proteins with uniquely significant differences in abundance compared to planktonic NTHI, which provided further evidence of the difference between the two NRel populations [Fig. 2b, purple versus orange sections].

We next annotated the DEPs by Clusters of Orthologous Groups of proteins (COG) [62,63] to assess the relative functions of the two NRel DEPs as a result of release from biofilm residence via distinct antibody-mediated dispersal versus disruption. For the anti-rsPilA NRel, annotation of the 63 DEPs revealed that the most frequently represented COG categories (36.5%) were involved in either energy production & conversion (19.0%) or amino acid transport & metabolism (17.5%) [Fig. 2c, purple bars & Suppl. Table 1]. Specific to energy production & conversion category, enzymes involved in glycolysis, tricarboxylic acid cycle, nitrogen metabolism, and anaerobic metabolism of glycerol were >1.5-fold decreased in abundance compared to planktonic NTHI. Whereas proteins involved in lactate uptake and utilization were >1.5 fold increased in abundance compared to planktonic NTHI [Suppl. Table 1]. In the same category, DEPs specific to anti-rsPilA NRel with >1.5-fold increase included transcripton biosynthesis and cysteine metabolism enzymes. The collective differences in protein functional categories indicated that anti-rsPilA NRel were primarily in an active-adaptive energy utilization and amino acid metabolic state.

In contrast, within the anti-IHF NRel population, ‘translation, ribosomal structure & biogenesis’ was the most frequently represented COG category (13.6%) among the 103 DEPs, compared to planktonic NTHI [Fig. 2c, orange bars & Suppl. Table 1]. Specific to anti-IHF NRel DEPs, eight were 30S and 50S ribosomal proteins with >1.5-fold increase, and although ribosomal structural proteins were also increased, two translation initiation factors were decreased >1.5-fold [Suppl. Table 1].
Further, expression of each of the cell envelope biogenesis, coenzyme metabolism, and lipid metabolism COG category proteins were >1.5-fold decreased compared to planktonic NTHI, for example, Lic2A, LicC, and LicD, proteins responsible for modification of lipooligosaccharide (LOS) and decoration with a phosphorylcholine moiety [64,65], and the lipid-protein carrier protein LolA, which shuttles lipoproteins from the inner membrane to the outer membrane [66]. Moreover, there were four anti-IHF NRel DEPs within the lipid metabolism category which were significantly >1.5-fold decreased in expression compared to planktonic NTHI [Fig. 2c]. Additionally, coenzyme metabolism proteins required for biosynthesis of biotin, a cofactor in fatty acid biosynthesis, were also significantly >1.5-fold decreased in expression [67]. In contrast, the outer membrane lipoprotein OMP P6, involved in maintenance of outer membrane integrity and attachment to peptidoglycan, and the major outer membrane protein OMP P2 were significantly increased in expression compared to planktonic NTHI [Suppl. Table 1] [68,69]. Collectively, these data suggested that anti-IHF NRel contained abundant ribosomes for translation of proteins, however translation was limited due to the reduced translation initiation factor proteins. Further, anti-IHF NRel demonstrated decreased expression of LOS-modifying enzymes and lipid metabolism genes, with a concurrent increase in expression of outer membrane integrity maintenance proteins, which suggested differences in membrane composition of anti-IHF NRel compared to planktonically grown NTHI.

The increased abundance of ribosomal proteins observed in the anti-IHF NRel proteomic profile is also characteristic of bacteria in lag phase of growth [70]. To determine whether anti-IHF NRel showed other similarities with lag phase bacteria, we used qRT-PCR to examine the expression of three genes canonically expressed by bacteria in lag phase [70]. Expression of desD, antM, and fis was significantly (>2-fold) upregulated in anti-IHF NRel vs. planktonic NTHI (Fig. S2a). Interestingly, for all three of these genes, the fold increase in transcript abundance over planktonic NTHI was significantly greater for anti-IHF NRel than for anti-rsPilA NRel (P < 0.05). Thus, that anti-IHF NRel appeared to be released from biofilm residence in a state which mimicked lag phase, presented another significant difference between the anti-IHF and anti-rsPilA phenotypes (Table 2), and again suggested that physical collapse of the biofilm structure resulted in rapid release while NTHI was metabolically more quiescent than anti-rsPilA NRel.

Because the proteomic expression profiles of the two NRel populations were different from each other [Fig. 2a], we next conducted a direct comparison of DEPs between the two NRel populations as depicted by volcano plot [Fig. 2d]. Fifty-one DEPs with >1.5-fold increase or decrease were identified amongst anti-IHF NRel versus anti-rsPilA NRel [Fig. 2d & Suppl. Table 1]. Of these, 15 proteins (29.4%) demonstrated a >1.5-fold increase in expression by anti-IHF NRel compared to anti-rsPilA NRel, and these proteins included five of the 3OS and 5OS ribosomal proteins described prior. Also, OMP P6 was more abundant in anti-IHF NRel compared to anti-rsPilA NRel. DEPs with a >1.5-fold decrease in the anti-IHF NRel compared to anti-rsPilA NRel (e.g. greater abundance in anti-rsPilA NRel) were characteristic of the abundantly expressed tryptophan biosynthesis proteins. These distinctions were in addition to relative differences in lipid metabolism proteins that had already been identified as decreased in expression in the anti-IHF NRel population compared to planktonic NTHI. Notably, this direct comparison of the two NRel proteomic expression profiles also revealed a significant increase in the peptidoglycan synthesis protein, MurB [71], within the anti-IHF NRel DEPs compared to anti-rsPilA NRel, which further suggested the altered cell envelope composition of the anti-IHF NRel [Suppl. Table 1].
Anti-rsPilA or anti-IHF NRel were significantly more sensitive to killing by a specific antibiotic than planktonic NTHI

With the observed significant differences in relative expression of distinct proteins between the two NRel populations demonstrated, we next examined how these differences altered phenotypic character. As bacteria newly released from a biofilm are typically more sensitive to killing by antibiotics than their planktonic counterparts [29,48,54,55], we assessed the sensitivity of NRel NTHI to TMP-SMX or to AMC, as these represent antibiotics commonly prescribed for NTHI-induced OM and respiratory infections [72–78]. We compared the anti-rsPilA NRel and anti-IHF NRel susceptibilities to killing by TMP-SMX or AMC, to that of both biofilm-resident NTHI (canonically highly resistant) and to planktonic NTHI grown to mid-log phase of growth (canonically sensitive and representative of the population commonly used to determine MIC values in clinical microbiology laboratories) [Fig. 3a]. To control for differences in the numbers of NTHI released by exposure to anti-IHF IgG for 15 min or by anti-rsPilA IgG for 6 h (see Fig. 1), we adjusted the density of the planktonic NTHI in each experiment to match that of either the anti-IHF or anti-rsPilA NRel population. After we identified the concentrations of AMC or TMP-SMX needed to reproducibly kill ∼25% of planktonic NTHI at each bacterial density, we then used these concentrations to assess relative killing of the corresponding NRel or biofilm-resident NTHI.

As expected, anti-rsPilA NRel were significantly more sensitive than biofilm-resident NTHI to killing by either TMP-SMX or AMC (P < 0.0001) [Fig. 3b,c]. Notably however, sensitivity of anti-rsPilA NRel to killing by TMP-SMX was significantly greater compared to that for planktonic NTHI (P ≤ 0.001) after only 2 h of antibiotic exposure [Fig. 3b]. In contrast, anti-rsPilA NRel were only equally as sensitive as their planktonic counterparts to killing by the β-lactam antibiotic AMC [Fig. 3c]. We then similarly evaluated anti-IHF NRel and found that they too were significantly more sensitive than biofilm-resident NTHI to killing by either TMP-SMX or AMC (P ≤ 0.0001), again as expected [Fig. 3d,e]. Intriguingly however, and in direct contrast to anti-rsPilA NRel, the anti-IHF NRel population was only equally as sensitive to TMP-SMX mediated killing as their planktonic counterparts [Fig. 3d], but significantly more sensitive to AMC (P < 0.0001) [Fig. 3e].

Bacterial sensitivity to antibiotic killing is the result of multiple processes that include drug uptake, efflux, and degradation, as well as the direct mechanism of antibiotic action [79]. To identify possible mechanisms for the selectively enhanced antibiotic sensitivities of anti-IHF or anti-rsPilA NRel, we used qRT-PCR to examine the relative expression of several genes likely to play a role in susceptibility or resistance to TMP-SMX or AMC. The protein targets of TMP and SMX, dihydrofolate reductase and dihydropteroate synthetase, are encoded by folA and folP, respectively; overproduction of FolA and FolP is associated with resistance to TMP-SMX [80]. Accordingly, we speculated that anti-rsPilA NRel NTHI would likely demonstrate less relative expression of folA and/or folP than anti-IHF NRel at the selected time points. Our results confirmed this hypothesis, as folA and folP expression were both significantly reduced in anti-rsPilA vs. anti-IHF NRel (Fig. 3b, P < 0.0001).

Efflux pumps enable bacteria to decrease the concentration of intracellular antibiotic. The Emr efflux system transports β-lactam antibiotics in Neisseria gonorrhoeae [81], and in E. coli, TMP-SMX exposure stimulates expression of the EmrAB efflux pump [82], which suggested that the EmrAB efflux pump could influence NRel sensitivity to TMP-SMX. We found that relative expression of emrA and emrB by anti-rsPilA NRel was significantly lower than anti-IHF NRel, which suggested the greater sensitivity of anti-rsPilA NRel to TMP-SMX (Fig. 3c, P < 0.001). In contrast, the ArcAB efflux pump can transport β-lactam antibiotics and is under the control of the transcriptional repressor acrR [83]. While enhanced AcrR expression via acrR mutations has been linked to amoxicillin resistance in Haemophilus (https://aac.asm.org/content/51/7/2564.long), we argued that enhanced expression of acrR would likely have the opposite effect, enhanced susceptibility of NTHI to AMC. As we anticipated, relative acrR expression was significantly greater by anti-IHF vs. anti-rsPilA NRel, consistent with the heightened sensitivity to AMC observed for anti-IHF NRel (Fig. S2c, P < 0.0001).

Taken together, our antibiotic sensitivity and transcript abundance data suggested that anti-rsPilA and anti-IHF NRel differed significantly in their relative antibiotic sensitivities due to the mechanism by which they were released from biofilm residence. However, we were concerned that the difference in time required for maximal disruption (minutes) vs. dispersal (hours) might have also played a role in the observed phenotype. Thereby, we repeated our analysis of relative antibiotic sensitivities on time-matched NRel populations recovered after incubation with either anti-rsPilA or anti-IHF IgG for 2 h, a timepoint approximately midway between the times of maximal release for both antibodies. Similar to the results shown in Fig. 3, anti-rsPilA NRel were significantly more susceptible to killing by TMP-SMX (P ≤ 0.0001) [Fig. 4a], and equally susceptible to killing by AMC, as planktonic NTHI (Fig. 4b). Moreover, time-matched anti-IHF NRel were again equally susceptible to killing by TMP-SMX (Fig. 4c) and significantly more susceptible to killing by AMC (P ≤ 0.0001) [Fig. 4d], compared to planktonic NTHI. These results provided further support for our hypothesis that the distinct antibiotic sensitivity phenotypes shown result from the different mechanisms of release, dispersal vs. disruption.

To date, we have shown extensive differences between the two mechanisms and outcomes of anti-rsPilA or anti-DNABII antibody-mediated release of biofilm-resident bacteria to the NRel state (Table 2). New data presented here added additional phenotypic distinctions between anti-rsPilA and anti-IHF NRel, wherein these two genetically identical populations exhibited not only distinctive proteomic and targeted transcriptomic expression profiles but also revealed that they were released from biofilm residence in distinct phases of growth and further, were released as either aggregates vs. as individual cells. Moreover, the two NRel populations demonstrated significantly increased, but different susceptibilities to killing by either a sulfonamide or a β-lactam antibiotic when compared to planktonic NTHI, both of which are first-line antibiotics recommended for treatment of NTHI-induced diseases.

Discussion

Historically, the development paths for vaccines and those for antibiotics have proceeded in parallel, with one focused on prevention and the other on treatment [84]. Whereas this strategy has indeed been successful for many diseases, we now face the issue of multiple chronic and recurrent infections for which neither path has yet achieved overall success. There are widely acknowledged obstacles to progress in this regard, none the least of which is the typically inherently slow vaccine development process [85]. Similarly, there are tremendous challenges to the antibiotic development pathway, with no clinically approved truly new class of drug introduced for >30 years, despite extensive effort necessitated by a worrisome rapid increase in the rise of multi-antibiotic-resistant bacteria worldwide [86,87]. These obstacles to progress are understandable given the complex and difficult-to-treat nature of chronic diseases, which has confounded both discovery pathways. Such persistent and recurrent infections are attributable to causative agents that form biofilms wherein the resident bacteria have a unique transcriptome and a highly recalcitrant phenotype that renders them resistant to antibiotics and host immune effectors that readily kill their planktonic counterparts [4,6,88–91]. Our advances in the recognition and understanding of the NRel phenotype now provide us with the opportunity to merge aspects of these development pathways to consider the use of therapeutic antibodies to release bacteria from the recalcitrant biofilm-residence into a state that is now markedly more vulnerable to killing.

In our previous studies, we showed that established NTHI biofilms concurrently exposed to both anticuerus against a bacterial DNABII protein and an antibiotic were significantly more sensitive to killing by three antibiotics commonly used to treat OM (e.g. ampicillin, AMC and cefditoren) at concentrations ∼4-fold below the MIC, compared to their planktonic counterparts [48]. We also showed that both NRel NTHI and NRel
Fig. 3. NRel NTHI populations were more sensitive to killing than their planktonic counterparts, and this sensitivity was distinct from each other. (a) Diagram of the four populations of NTHI tested herein. NRel were generated by incubation of NTHI biofilms with rabbit polyclonal IgG isolated from anti-rsPilA serum (6 h, purple) or from anti-IHF serum (15 min, orange). (b & c) Anti-rsPilA NRel were significantly more sensitive to killing by trimethoprim/sulfamethoxazole than planktonic NTHI (TMP-SMX at 0.94 µg and 4.7 µg per ml respectively, panel b), but only equally as sensitive to killing by amoxicillin/clavulanate (AMC at 2.5 µg and 1.25 µg per ml, respectively panel c). Biofilm-resident NTHI displayed minimal sensitivity to either TMP-SMX or AMC as expected. (d & e) In contrast, anti-IHF NRel were only equally as sensitive to killing by TMP-SMX as planktonic NTHI (0.09 and 0.45 µg/ml respectively, panel d), but significantly more sensitive to killing by AMC (0.30 and 0.15 µg/ml respectively, panel e). The uniquely heightened sensitivity of NTHI NRel to killing by either TMP-SMX or AMC was dependent upon the mechanism by which they were released from biofilm residence. Individual data points are shown, bars represent mean ± SEM. ***P < 0.001, ****P < 0.0001, one-way analysis of variance with the Holm-Sidak correction. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
expression of targeted genes and sensitivity to killing by antibiotics were distinct not only from planktonically grown NTHI, but importantly, also from each other. Although the kinetics of release by anti-IHF-mediated disruption vs. anti-rsPilA-mediated dispersal are clearly different, our results strongly suggest that the observed differences in NRel phenotype were dependent on the specific antibody that mediated release from biofilm residence. The proteomic expression profiles provided a snapshot in time of the total released NRel populations. The anti-rsPilA NRel population proteomic profile was defined by an adaptive state of energy metabolism & conversion and amino acid transport & metabolism in response to their being induced to actively disperse from the biofilm. This adaptive metabolic state is likely somewhat more heterogeneous than anti-IHF NRel due to the more gradual release of cells as they actively disperse from the biofilm due to expression of both AI-2 and the Type IV twitching pilus over the 6 h incubation period. Nonetheless, the adaptive metabolic state of this anti-rsPilA NRel population was very similar to that described for other genera (e.g. S. pneumoniae, K. pneumoniae, and P. aeruginosa) in response to release from a biofilm and thereby does not appear to be atypical [92-94].

In analysis of the anti-IHF NRel population, we found that it was defined by an increased production of ribosomal proteins with a concurrent decrease in LOS modification, cell membrane maintenance and lipid metabolism proteins. The enrichment of ribosomal proteins suggested that the anti-IHF NRel population was poised for protein synthesis with an altered membrane composition in response to rapid passive release en masse into the surrounding milieu. As such, anti-IHF NRel might be expected to still largely resemble biofilm-resident NTHI bacteria. Indeed, targeted transcriptomics indicated that anti-IHF NRel were in a state of growth similar to lag phase. Nonetheless, the anti-IHF NRel phenotype was also clearly different from that of biofilm-resident NTHI, as revealed by their significantly greater killing by both sulfonamide and β-lactam antibiotics compared to biofilm-resident NTHI.

As expected from our previous work [29,48], NRel NTHI were highly sensitive to two first-line antibiotics prescribed to treat NTHI-induced diseases. However, here we showed for the first time that these NRel populations displayed unique enhanced sensitivity to killing by a different class of antibiotic dependent on whether they had been released from biofilm residence by either dispersal (e.g. via anti-rsPilA) or disruption (e.g. via anti-IHF). These differences cannot be explained by a direct effect of either anti-rsPilA or anti-IHF on NRel NTHI, since neither NTHI viability or susceptibility to killing by either of these antibiotics is disrupted (e.g. via anti-IHF). These differences cannot be explained by a direct effect of either anti-rsPilA or anti-IHF on NRel NTHI, since neither NTHI viability or susceptibility to killing by either of these antibodies is affected by incubation with either antibody [29,48]. Collectively, the two resultant NRel populations showed significant differences in relative proteomic expression profiles, targeted transcriptomic profiles, character of release from biofilm residence (both growth phase and as single cells vs. aggregates), and antibiotic sensitivities.

The anti-rsPilA NRel adaptive amino acid transport & metabolism state provided insight into the mechanism of this population’s uniquely increased susceptibility to TMP-SMX, because the sulfonamide class of antibiotic targets the folic acid synthesis pathway involved in amino acid synthesis [95]. Also, compared to anti-IHF NRel, the lower relative expression of folA and folP, which encode the protein targets for TMP and SMX, respectively, together with lower expression of emrA and emrB, which encode subunits of the EmrAB \\*efflux pump that transports TMP-SMX out of the cell, also supported the greater sensitivity to TMP-SMX of anti-rsPilA vs. anti-IHF NRel. Similarly, the differences noted in the anti-IHF NRel lipid metabolism and cell membrane composition proteins supported the observed increased sensitivity to AMC, wherein the modified membrane content could have altered membrane permeability to allow greater access of the β-lactam antibiotic to the periplasm where they could bind to the penicillin binding proteins to prevent peptidoglycan crosslinking [96]. Additional insight into the mechanism of unique sensitivity to the β-lactam antibiotic in the anti-IHF NRel population was provided by the increased abundance of the peptidoglycan synthesis protein MurB, which suggested that the anti-IHF NRel were actively synthesizing peptidoglycan which would support
their greater susceptibility to the action of a β-lactam antibiotic [96,97]. The upregulation of \acrR, which represses expression of AcrAB efflux pump, likely results in increased AMC concentration within the anti-IHF NRel and enhanced killing. The upregulation of fis in the anti-IHF NRel population presents yet another possible mechanism for increased sensitivity to AMC, since both \textit{P. aeruginosa} and \textit{E. coli} mutants with a nonfunctional fis gene showed enhanced resistance to a β-lactam antibiotic [98–100]. In addition to the possible mechanisms discussed above, many other factors, such as accessibility to the bacteria released from the biofilm matrix into the surrounding milieu, combined with overall changes in metabolic activity and/or alterations in membrane content and permeability could all have likely contributed to the observed susceptibilities to the specific class of antibiotic shown, as well as perhaps additional classes of antibiotics not yet tested. This premise is currently under investigation as we continue to further define the phenotypes of anti-rsPilA and anti-IHF NRel NTHI.

Taken together, our data suggested that the NRel phenotype is not ‘generic,’ but rather highly distinct and dependent on the antibody-mediated mechanism of release of NTHI from biofilm residence. Given that we’ve already shown that NRel NTHI are rapidly eradicated in vivo by either immune effectors alone [33,49] or when needed, in combination with co-delivered antibiotics (but now at a reduced dose) [32], it is clear that while there are phenotypic distinctions, NRel NTHI and other NRel bacterial species [29,48,54–56], appear to be in a highly vulnerable state wherein they can be much more effectively eliminated. Further investigation to characterize the likely manifold distinctions between NRel NTHI populations will include examination of environmental conditions under which biofilms are formed, maturation status and character of biofilms formed by diverse strains of NTHI as well as other genera of bacteria. Furthermore, since the two NRel populations described here represent an adaptive state, the NRel phenotype is likely dynamic over time. Indeed, dissecting the contribution of release kinetics and means to disperse or disrupt biofilms will be a focus of future investigations to fully characterize the onset and duration of the distinct antibiotic-sensitive phenotypes.

In a world ‘running out of antibiotics’ [101] there is a push to identify new antimicrobials, institute antibiotic stewardship and educate the public as to the dangers of inappropriate antibiotic use [102]. This situation has inspired many to attack this problem in novel and creative ways. In a Nature commentary, Rappuoli, Bloom and Black [103] suggested we combine the power of vaccine-induced antibodies with a more appropriate use of antibiotics as our “last hope against multi-drug resistant bacteria and persistent disease”. Whereas their focus was on antibodies that reduce carriage, and thus transmission of antibiotic-resistant bacteria [103], we envision use of specifically induced antibodies to release biofilm-resident NTHI from these highly resistant communities so they can be killed by host immune effectors and when necessary, traditional antibiotics, with the latter now used at a markedly reduced dose and for a shorter course due to the highly sensitive phenotype of NRel NTHI. An additional potential benefit of a less frequent antibiotic treatment regimen is reduction of off-target side effects and other undesirable sequelae of oral antibiotic use; which includes development of antibiotic resistance [84,104] and/or disruption of the gut microbiome [16, 105–108].

Herein, we provide proof-of-principle for this strategy to treat biofilm-associated diseases caused by NTHI via use of NRel-inducing antibodies directed against unique biofilm associated targets of this important human pathogen. Moreover, use of the species independent anti-DNABI approach broadens the potential use of this combination strategy for treatment of many other diseases caused by diverse human pathogens wherein a biofilm similarly contributes significantly to pathogenesis, chronicity, recurrence and relapse to treatment. Recent humanization and demonstrated efficacy of NRel-inducing monoclonal antibodies directed against a DNABI protein both \textit{in vivo} and in vitro is expected to expedite transition to human clinical trials [109,110].

CRediT authorship contribution statement

Elaine M. Mokrzan: Investigation, Methodology, Visualization, Formal analysis, Writing - review & editing. Christian P. Ahearn: Investigation, Methodology, Visualization, Formal analysis, Writing - review & editing. John R. Buzzo: Investigation, Methodology, Formal analysis, Writing - review & editing. Laura A. Novotny: Visualization, Formal analysis, Writing - review & editing. Yan Zhang: Formal analysis, Software, Writing - review & editing. Steven D. Goodman: Conceptualization, Formal analysis, Writing - review & editing, Supervision.

Lauren O. Bakaletz: Conceptualization, Resources, Formal analysis, Writing - original draft, preparation, Writing - review & editing, Supervision.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L.O.B. and S.D.G. are the inventors of technology related to the DNABII proteins, rights to which have been licensed to Clarameytx Biosciences, Inc. L.O.B. is an inventor of technology related to PilA-derived immunogens that is licensed to GlaxoSmithKline Biologicals. E.M.M., C.P.A., J.R.B., L.A.N., and Y.Z. have no interests to declare.

Acknowledgements

The authors are grateful to Aishwarya Devaraj, Ph.D. for thoughtful discussions. The authors thank Joseph Jurcisek for critical manuscript review and Jennifer Neelans for outstanding assistance with manuscript preparation.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.biofil.2020.100039.

Funding sources

This work was supported by the National Institutes of Health [NIH/NIDCD R01 DC003915 to LOB and NIH/NIDCD R01 DC011818 to LOB & SDQ] as well as discretionary funds to LOB. Y.Z was partially supported by The Ohio State University Comprehensive Cancer Center [P30CA16058].

References

[1] Dongari-Bagtzoglou A. Pathogenesis of mucosal biofilm infections: challenges and progress. Expert Rev Anti Infect Ther 2008;6:201–8. https://doi.org/10.1586/14787210.6.2.201.
[2] Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318–22. https://doi.org/10.1126/science.284.5418.1318.
[3] Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol 2010;8: 623–33. https://doi.org/10.1038/nrmicro2415.
[4] Ahearn CP, Gallo MC, Murphy TF. Insights on persistent airway infection by non-typeable \textit{Haemophilus influenzae} in chronic obstructive pulmonary disease. Pathog Dis 2017;75. https://doi.org/10.1093/femspd/ftx042.
[5] Cardines R, Giufre M, Possa A, Piscatelli E, Ricciotti G, Di Bonaventura G, Cercuetti M. \textit{Haemophilus influenzae} in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int J Med Microbiol 2012;302:45–52. https://doi.org/10.1016/j.ijmm.2011.08.003.
[6] Pang B, Hong W, Kock ND, Swords WE. Dps promotes survival of nontypeable \textit{Haemophilus influenzae} in biofilm communities in vitro and resistance to clearance in vivo. Front Cell Infect Microbiol 2012;2:58. https://doi.org/10.3389/fcimb.2012.00058.
[7] Barkal G, Lebovitz E, Givon-Lavi N, Dagan R. Potential contribution by nontypeable \textit{Haemophilus influenzae} in protracted and recurrent acute otitis media. Pediatr Infect Dis J 2009;28:466–71. https://doi.org/10.1097/inf.0b013e31819050c74.
[8] Cleary D, Devine V, Morris D, Osman K, Gladstone R, Bentley S, Faust S, Clarke S. Pneumococcal vaccine impacts on the population genomics of non-typeable
Haemophilus influenzae. Microb Genom 2018;4:e000209. doi.org/10.1099/mgen.0.000209.

[49] Greaves M, Warden J, Bohn JC, Bliau W, Harder T, Kroeniger W, Vetter V, Pircon JY, Marando C. Identification and characterization of the bacterial etiology of clinically problematic acute otitis media after tympanocentesis or spontaneous otitis in German children. BMC Infect Dis 2012;12:312. doi.org/10.1186/1471-2334-12-312.

[50] Vergison A. Microbiology of otitis media: a moving target. Vaccine 2008;26(Suppl 7):G5–10. doi.org/10.1016/j.vaccine.2008.11.006.

[51] Wiertsema SP, Kirkham LA, Cascadden KJ, Mowe EN, Bowman JM, Jacoby P, Bottcher A, Fleischer NL, Doern GV, Group GS. Reporting rates of diarrhea and acute respiratory disease following exposure to antibiotics in pregnancy. antenatally, intrapartum and neonatally 2020;F1000Res 9:F1000.https://doi.org/10.12688/f1000research.140.

[52] Novotny LA, Dean DF, Hall DJ, Devaraj A, Goodman SD, Bakaletz LO. Antibodies against DNA-binding tips of DANBI antibodies disrupt biofilms in vitro and induce bacterial clearance in vivo. EBioMedicine 2016;10:33–44. https://doi.org/10.1016/j.ebiom.2016.01.017.

[53] Novotny LA, Jurcisek JA, Ward Jr MO, Jordan ZB, Goodman SD, Bakaletz LO. Antibodies against the majority subunit of type IV Pilus disperse nontypeable Haemophilus influenzae biofilms in a LuxS-dependent manner and confer therapeutic resolution of experimental otitis media. Mol Microbiol 2015;96:276–92. https://doi.org/10.1111/mmi.12935.

[54] Yseaebaert C, Donzel P, Weynants V, Bakaletz LO, Novotny LA, Godfried F, Hermand F. A protein-E-FIA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun 2019;87. https://doi.org/10.1128/IAI.00345-19. e00345-003019.

[55] Armbruster CE, Hong W, Pang B, Dew KE, Juneau RA, Byrd MS, Love CF, Kock ND, Swords WE. LuxS promotes biofilm maturation and persistence of nontypeable Haemophilus influenzae in vivo via modulation of polysaccharides on the bacterial surface. Infect Immun 2009;77:4081–91. https://doi.org/10.1128/IAI.00230-09.

[56] Daines DA, Bothwell M, Furrer J, Unrath W, Nelson K, Jurich J, Melrose N, Greiner L, Apicella M, Smith AL. Haemophilus influenzae luxS mutants form biofilm and have increased virulence. Microb Pathog 2005;38:79–86. https://doi.org/10.1016/j.micpath.2005.06.003.

[57] Surette MG, Miller MB, Basliner BL. Quorum sensing in Escherichia coli. Salmonella typhimurium, and Vibrio harveyi: a new family of genes responsible for quorum sensing. Proc Natl Acad Sci U S A 1999;96:1639–44. https://doi.org/10.1073/pnas.96.4.1639.

[58] Armbruster CE, Pang B, Muruhan K, Juneau RA, Perez AC, Wehester KE, Swaths WE. RhbD (NTH_0362) mediates quorum signal uptake in nontypeable Haemophilus influenza strain 86-028NP. Mol Microbiol 2011;82:836–50. https://doi.org/10.1111/j.1365-2958.2011.07851.x.

[59] Pang B, Armbruster CE, Foster G, Learman BS, Gandhi U, Swords WE. Autosensor 2 (12–20) production by nontypeable Haemophilus influenzae 86-028NP promotes expression of a predicted glycosyltransferase that is a determinant of biofilm maturation, prevention of dispersal, and persistence in vivo. Infect Immun 2018;86. https://doi.org/10.1128/IAI.00565-18.

[60] Armbruster CE, Hong W, Pang P, Juneau RA, Turner J, Swords WE. Indirect pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in polymicrobial otitis media occurs via interspecies quorum signaling. mBio 2010;1. https://doi.org/10.1128/mBio.00020-10.

[61] Kamashev D, Agapova Y, Rastorguev S, Talyzina AA, Boyko KM, Korzhenevsky DA, Vlasina A, Vasilov RV, Timofeev VI, Rakitina TV. Comparison of histone-like Hu protein DNA-binding properties and Hu/HF protein sequence alignment. PLoS One 2017;12:e0188037. https://doi.org/10.1371/journal.pone.0188037.

[62] Devaraj A, Buizzo J, Rocco CJ, Bakaletz LO, Goodman SD. The DANBI family of proteins is comprised of the only nucleic acid associated proteins required for nontypeable Haemophilus influenzae biofilm structure. Microbiology 2018;164:565–568. https://doi.org/10.1099/jmm.0.000530-5.

[63] Devaraj A, Justice SS, Bakaletz LO, Goodman SD. DANBI proteins play a central role in UPEC biofilm structure. Mol Microbiol 2015;96:1119–35. https://doi.org/10.1111/mmi.12994.

[64] Novotny LA, Amer AO, Brockmeyer ME, Goodman SD, Bakaletz LO. Structural stability of Burkholderia cenocepacia biofilms is reliant on DNA structure and presence of a bacterial nucleic acid binding protein. PLoS One 2013;8:e67629. https://doi.org/10.1371/journal.pone.0067629.

[65] Goodman SD, Oberfell KP, Jurcisek JP, Justice SS, Bakaletz LA, Downey JS, Ayala EA, Tjokro N, Li B, Justice SS, Bakaletz LO. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleic-acid-associated proteins. Mucosal Immunol 2014;7:625–37. https://doi.org/10.1038/mi.2014.55.

[66] Jurcisek JA, Bakaletz LO. Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. J Bacteriol 2007;189:3868–75. https://doi.org/10.1128/JBC.00563-06.

[67] White EG, Barlow PC, Tsuji M, M ACKay JD, Bakaletz LO, Goodman SD, Bakaletz LO, Goodman SD, Bakaletz LO. Role of action of anti-integration host factor-mediated disruption of bacterial biofilm viability. Mol Microbiol 2014;93:1246–58. https://doi.org/10.1111/mmi.12735.

[68] Devaraj A, Goodman SD, Bakaletz LO, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoproducts of a DANBI protein evolves experimental otitis media. NPJ Vaccines 2019;4:43. https://doi.org/10.1038/s41541-019-0037-1.

[69] Brockmeyer ME, Devaraj A, Young A, Navarro JR, Downey JS, Chen C, Bakaletz LO, Zadeh HL, Goodman SD. A bacterial biofilm-induced oral leukocytic infection can be successfully treated by immuno-targeting an extracellular nucleic-associated protein. Mol Oral Microbiol 2017;12:74–84. https://doi.org/10.1251/mo.2016.00031.1251.

[70] Choffart S, Liu Y, Vamvakopoulos C, Chen Y, Veborg BM, Tan BG, Koelega S, Tolker Nielsen T, Gribkov M, York J. Distinct stage in the
transition from bacterial biofilm to planktonic lifestyles. Nat Commun 2014;5: 4462. https://doi.org/10.1038/ncomms5402.

[52] Marks LR, Davidson KA, Knight PR, Hakkanson AP. Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. mBio 2013;4. https://doi.org/10.1128/mBio.00438-13. e00438-13.

[53] Sauer K, Cullen M, Nicodemus AH, Zeef LA, Davies DG, Gilbert P. Characterization of nutrient-induced dispersion in Pseudomonas aeruginosa PA01 biofilm. J Bacteriol 2004;186:7312–26. https://doi.org/10.1128/JB.186.21.7312-7326.2004.

[54] Chambers JR, Cherry KE, Sauer K. Susceptibility of Pseudomonas aeruginosa dispersed cells to antimicrobial agents is dependent on the dispersion cue and class of the antimicrobial used. Antimicrob Agents Chemother 2017;61. https://doi.org/10.1128/AAC.01055-17.

[55] Goodwin J, Gil J, Deonor J, Valdes J, Solis M, Higa A, Davis S, Sauer K. Pynvurate-depleting conditions induce biofilm dispersion and enhance the efficacy of antibiotics in killing biofilms in vitro and in vivo. Sci Rep 2019;9:3763. https://doi.org/10.1038/s41598-019-40378-z.

[56] Petrova OI, Sauer K. Escaping the biofilm in more than one way: desorption, detachment or dispersion. Curr Opin Microbiol 2016;32:67–77. https://doi.org/10.1016/j.mib.2016.01.004.

[57] Harrison A, Dyer DW, Gillary A, Ray WC, Mungur B, Carson MB, Zhong H, Gipson J, Gipson M, Johnson LS, Lewis I, Bakaleto LO, Muxson Jr RS. Genomic sequence of an otitis media isolate of nontypeable Haemophilus influenzae: comparative study with H. influenzae serotype d, strain KW20. J Bacteriol 2005;187:4627–36. https://doi.org/10.1128/JB.187.11.4627-4635.2005.

[58] Sirakova T, Kolattukudy PE, Murwin D, Billy J, Leake E, Lim D, DeMaria T, Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R. Susceptibilities of Haemophilus influenzae and antibiotic susceptibility of non-typeable Haemophilus influenzae. J Infect Dis 2013;208:720–8. https://doi.org/10.1093/infdis/jit514.

[59] Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic aspergilliosis. J Asthma Allergy Clin Pharmacol 2017;33:300–5. https://doi.org/10.1007/s41023-017-0193-y.

[60] Aziz A, Sarovich DS, Norwestor B, Elsharbaty I, Murphy TF, Kirkham C, Lesse AJ. Construction of a mutant and characterization of the lipo-oligosaccharides of Haemophilus influenzae. mBio 2013;4. https://doi.org/10.1128/mBio.01055-12.

[61] Swords WE, Jones PA, Apicella MA. The lipo-oligosaccharides of Haemophilus influenzae up to date. J Bacteriol 2004;186:7312–26. https://doi.org/10.1128/JB.186.21.7312-7326.2004.

[62] Tatusov RL, Galperin MY, Natale DA, Koonin EV. The COG database: a tool for global alignment of protein families. Nucleic Acids Res 2003;31:319-322. https://doi.org/10.1093/nar/gkg783.

[63] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.

[64] Aziz A, Sarovich DS, Norwestor B, Elsharbaty I, Murphy TF, Kirkham C, Lesse AJ. Construction of a mutant and characterization of the lipo-oligosaccharides of Haemophilus influenzae up to date. J Bacteriol 2004;186:7312–26. https://doi.org/10.1128/JB.186.21.7312-7326.2004.

[65] Tatsis Niki K, Favini-Stabile S, Dessen A. Resistance to antibiotics targeted to the lipo-oligosaccharides of Haemophilus influenzae. J Antimicrob Chemother 2017;73:27–32. https://doi.org/10.1093/jac/dkw358.

[66] K LCH, Akyol S, Parkan OM, Dinc G, Sav H, Aydemir G. Molecular characterization and antibiotic susceptibility of Haemophilus influenzae clinical isolates. Inf Med 2017;25:7–27. https://doi.org/10.1016/j.imed.2017.06.033.

[67] Pelton S. In: Post T, editor. Acute otitis media in children: Treatment. Walhain, MA: UpToDate; 2020.

[68] Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355–65. https://doi.org/10.1056/NEJMoa0803553.

[69] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.

[70] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.

[71] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.

[72] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.

[73] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.

[74] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.

[75] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.

[76] Taglaiabae A, Rappuoli R. Changing priorities in vaccinology: antibiotic resistance moving to the top. Front Immunol 2018;9:1901. https://doi.org/10.3389/fimmu.2018.01901.
Rappuoli R, Bloom DE, Black S. Deploy vaccines to fight superbugs. Nature 2017; 552:165–7. https://doi.org/10.1038/s41586-017-08323-0.

Patini R, Mangino G, Martellacci L, Quaranta G, Manucci L, Galleni P. The effect of different antibiotic regimens on bacterial resistance: a systematic review. Antibiotics 2020;9:22. https://doi.org/10.3390/antibiotics9010022.

Bailey MT, Lauber CL, Novotny LA, Goodman SD, Bakaletz LO. Immunization with a biofilm-disrupting nontypeable Haemophilus influenzae vaccine antigen did not alter the gut microbiome in chinchillas, unlike oral delivery of a broad-spectrum antibiotic commonly used for otitis media. mSphere 2020;5. https://doi.org/10.1128/mSphere.00296-20. e00296-00220.

Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glanziu P, Del Mar C. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. CMAJ (Can Med Assoc J) 2015;187:E21–31. https://doi.org/10.1503/cmaj.140848.

MacPherson CW, Mathieu O, Tremblay J, Champagne J, Nantel A, Girard SA, Tompkins TA. Gut bacterial microbiota and its resistome rapidly recover to basal state levels after short-term amoxicillin-clavulanic acid treatment in healthy adults. Sci Rep 2018;8:11192. https://doi.org/10.1038/s41598-018-29229-5.

Pallas K, Doved SE, Villahuerre J, Yang X, Kabbani T, Hansen J, Dennis M, Leffler DA, Newburg DS, Kelly CP. Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial. Gut Microbiol 2014;5:458–67. https://doi.org/10.4161/gmic.29556.

D’Andrea MM, Lau GW. DNABII targeting antibodies as vaccines against biofilm diseases. EBioMedicine 2020;58:102921. https://doi.org/10.1016/j.ebiom.2020.102921.

Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine 2020. https://doi.org/10.1016/j.ebiom.2020.102867.